Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Postpartum depression (PPD) is a significant mood disorder with limited treatment options.
• GH001, an inhaled formulation of mebufotenin (5-MeO-DMT), is being investigated for PPD treatment.
• Existing therapies for PPD often have limitations in efficacy and tolerability.

Purpose of the Study:

• To evaluate the preliminary efficacy and safety of GH001 in adult females diagnosed with PPD.
• To assess the impact of GH001 on depressive symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS).
• To determine the response and remission rates, as well as the safety and tolerability of GH001.

Main Methods:

• A phase 2a, open-label, proof-of-concept trial involving 10 women aged 18-45 with PPD and baseline MADRS scores ≥28.
• GH001 was administered via inhalation with individualized escalating doses (6, 12, 18 mg) on day 1.
• Primary endpoint: change in MADRS score from baseline to day 8. Secondary endpoints: antidepressant response, remission, safety, and tolerability.

Main Results:

• A significant reduction in mean MADRS total score from baseline to day 8 (-35.4 points, P < .0001).
• All 10 patients achieved antidepressant response and remission by day 8, with remission observed as early as 2 hours post-dose.
• GH001 was well-tolerated, with no serious adverse events reported; most adverse events were mild to moderate, primarily headache.

Conclusions:

• GH001 demonstrated rapid and significant efficacy in improving depressive symptoms and achieving remission in patients with PPD.
• The inhaled formulation of mebufotenin showed an acceptable safety and tolerability profile.
• GH001 represents a promising novel therapeutic option for postpartum depression.